Since 1995, the American Academy of Neurology has provided guidelines for brain death determination, but nationwide adherence to these guidelines has been incomplete.
AMA J Ethics. 2020;22(12):E1027-1032. doi:
10.1001/amajethics.2020.1027.
Dr Ariane Lewis discusses how we can navigate uncertainty and ambiguity about brain death by understanding clinical criteria for brain death determination and how our approaches to death are culturally and socially situated.
Adhering too strictly to biomedical thinking about diagnosis can prevent clinicians from empathically engaging with patients and helping them navigate their illness experiences.
AMA J Ethics. 2021;23(7):E537-541. doi:
10.1001/amajethics.2021.537.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.